nVerses Capital’s Aldeyra Therapeutics ALDX Stock Holding History

nVerses Capital’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,700	Closed	-$5.63K	–	975
2024 Q2	$5.63K	Buy	+1,700	New	+$6.66K	﹤0.01%	951

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

nVerses Capital's ALDX Position: Q3 2024 in Review

nVerses Capital sold out of Aldeyra Therapeutics (ALDX) in Q3 2024, closing a stake of 1,700 shares — an estimated $5.63K sold.

nVerses Capital first reported a position in ALDX in Q2 2024 and held it in 1 quarter. The position peaked at $5.63K in Q2 2024. 112 funds tracked by Wall St. Rank hold ALDX as of Q3 2024.

nVerses Capital reported no remaining Aldeyra Therapeutics position as of Q3 2024 after selling out during the quarter.
nVerses Capital sold 1,700 Aldeyra Therapeutics shares in Q3 2024, an estimated $5.63K.
nVerses Capital first reported a position in Aldeyra Therapeutics in Q2 2024 and held it in 1 quarter.
nVerses Capital's Aldeyra Therapeutics position peaked at $5.63K in Q2 2024.
112 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2024.

Based on nVerses Capital's 13F filing for Q3 2024, filed 16 Oct 2024.